Search Results

You are looking at 61 - 70 of 2,540 items for :

  • Refine by Access: All x
Clear All
Full access

Andrew Trunk, Matthew Braithwaite, Christopher Nevala-Plagemann, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna

the poor outcomes associated with BRAF mt mCRC. Although potential improvement in survival with FOLFOXIRI has been suggested, current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer (Version 4.2020) still do not give

Full access

Vivek Verma, Swati M. Surkar, Eric D. Brooks, Charles B. Simone II, and Chi Lin

study of a large, contemporary national database of a general US population aimed to evaluate national practice patterns and outcomes of unresected nonmetastatic GC receiving CT alone versus CRT. Although challenging to assess with single- or multi

Full access

Siu-Fun Wong, Mark Bounthavong, Cham P. Nguyen, and Timothy Chen

provide the convenience for self-medication at home; however, they increase the risks for nonadherence, drug interactions, and adverse drug events (ADEs), which may threaten therapeutic outcomes and patient safety. 2 Oral chemotherapy drugs are perceived

Full access

Matthew A. Gubens and Marianne Davies

to have much poorer outcomes with single-agent immunotherapy. PD-L1 Expression ≥50% In KEYNOTE-024, pembrolizumab more than doubled median overall survival (mOS) compared with chemotherapy for patients with PD-L1 expression ≥50%, improving mOS to 30

Full access

Katherine Y. Fan, Avani S. Dholakia, Aaron T. Wild, Zheng Su, Amy Hacker-Prietz, Rachit Kumar, Mary Hodgin, Charles C. Hsu, Dung T. Le, Ana De Jesus-Acosta, Luis A. Diaz Jr, Daniel A. Laheru, Ralph H. Hruban, Elliot K. Fishman, Todd D. Brown, Timothy M. Pawlik, Christopher L. Wolfgang, Phuoc T. Tran, and Joseph M. Herman

outcomes of hospitalized patients with cancer in terms of infection, mortality, length of stay, and toxicities. The risk of cancer death (from stomach, liver, lung cancers) has been noted to be significantly higher among those with a high fasting plasma

Full access

Richard Li, Ashwin Shinde, Marwan Fakih, Stephen Sentovich, Kurt Melstrom, Rebecca Nelson, Scott Glaser, Yi-Jen Chen, Karyn Goodman, and Arya Amini

data addressing management of this rare malignancy, we used the National Cancer Database (NCDB) to assess survival outcomes according to stage and treatment strategy in patients with anal adenocarcinoma. We focused our investigation on a comparison of

Full access

Lauren Lapointe-Shaw, Hani Abushomar, Xi-Kuan Chen, Katerina Gapanenko, Chelsea Taylor, Monika K. Krzyzanowska, and Chaim M. Bell

measurement have been used to address this problem by clearly delineating best practices. 2 Although many improvement efforts have centered on the coordination of outpatient care services, there are few studies of in-hospital care processes and their outcomes

Full access

Emily J. Martin, Eric J. Roeland, Madison B. Sharp, Carolyn Revta, James D. Murphy, Katherine E. Fero, and Heidi N. Yeung

-center, retrospective study, we evaluated PCA use and associated clinical outcomes in patients admitted to the hospital with cancer-related pain, defined as acute or chronic physical pain attributed to cancer or its treatment. Methods Study Cohort All

Full access

Tami Borneman, Barbara F. Piper, Virginia Chih-Yi Sun, Marianna Koczywas, Gwen Uman, and Betty Ferrell

health care outcomes? JAMA 1999 ; 282 : 867 – 874 . 23. Allard P Maunsell E Labbe J Dorval M . Educational interventions to improve cancer pain control: a systematic review . J Palliat Med 2001 ; 4 : 191 – 203 . 24. Ferris FD

Full access

Alexandra K. Zaleta, Shauna McManus, Joanne S. Buzaglo, Eva Y. N. Yuen, Julie S. Olson, Melissa F. Miller, Karen Hurley, Lillie D. Shockney, Sara Goldberger, Mitch Golant, and Kevin Stein

Background: Despite growing recognition that patient preferences and values should inform cancer care, patients’ views continue to be under-represented. We developed a quantitative tool, Valued Outcomes in the Cancer Experience (VOICE), to measure